|LETTER TO EDITOR
|Year : 2020 | Volume
| Issue : 3 | Page : 653
Authors' reply to Kies and Katna et al.
Vijay M Patil, Vanita Noronha, Amit Joshi, Sachin Dhumal, Nandini Menon, Kumar Prabhash
Department of Medical Oncology, Tata Memorial Centre, HBNI, Mumbai, Maharashtra, India
|Date of Submission||07-Jul-2020|
|Date of Decision||10-Jul-2020|
|Date of Acceptance||16-Jul-2020|
|Date of Web Publication||19-Sep-2020|
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Patil VM, Noronha V, Joshi A, Dhumal S, Menon N, Prabhash K. Authors' reply to Kies and Katna et al. Cancer Res Stat Treat 2020;3:653
We thank Kies and Katna et al. for their interest in our study and the accompanying editorial. We agree with the comments made by Dr. Kies. A prospective Phase II study with an innovative design and Bayesian statistics is required. However, a long duration of follow-up is necessary, especially for esthesioneuroblastoma. Further, as pointed out by Dr. Kies, the treatment advances might make the approach outdated. Hence, there is a need to develop biomarkers and reliable short-term endpoints which could be used to address these concerns.
To answer Katna et al.'s query regarding the long-term survival outcomes in patients who underwent surgical resection with appropriate adjuvant treatment as compared to patients who received no surgery, we would like to mention that the required analysis was performed and presented in [Figure 3] and [Figure 5] of the article. The factor “operability” used in the figures divides the patients into two groups based on whether or not they were surgically operated. As depicted, there was no statistically significant difference in the outcomes between these two groups. We agree that the metabolic complications reported by us are higher than those reported in germ cell tumors. However, there is a biological reason for this. All the patients received neoadjuvant chemotherapy, and except three, all had received radiation. The radiation portals in sinonasal tumors encompass the pituitary gland and, to a variable extent, the hypothalamus. Radiation to the pituitary gland and hypothalamus can predispose the patients to the development of a metabolic syndrome due to endocrine insufficiency.,
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kies M. Does induction chemotherapy advance the multimodal treatment of locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation? Cancer Res Stat Treat 2020;3;650-1.
Katna R, Kalyani N, Bhosale B. Changing treatment paradigms in advanced sinonasal neuroendocrine cancers. Cancer Res Stat Treat 2020;3:651-2. [Full text]
Patil VM, Noronha V, Joshi A, Talreja V, Dhumal S, Menon N, et al
. Long-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy. Cancer Res Stat Treat 2020;3:201-6. [Full text]
Limaye S, Shreenivas A. Who knows the nose? – The tale of esthesioneuroblastoma and sinonasal neuroendocrine carcinoma. Cancer Res Stat Treat 2020;3:293-5. [Full text]
Bhattacharjee A, Vishwakarma GK, Banerjee S. A Bayesian approach for dynamic treatment regimes in the presence of competing risk analysis. Cancer Res Stat Treat 2018;1:51-7. [Full text]
Patil VM, Joshi A, Noronha V, Sharma V, Zanwar S, Dhumal S, et al
. Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation). Int J Surg Oncol 2016;2016:6923730.
Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, et al
. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103:2761-84.
Cooksey R, Wu SY, Klesse L, Oden JD, Bland RE, Hodges JC, et al.
Metabolic syndrome is a sequela of radiation exposure in hypothalamic obesity among survivors of childhood brain tumors. J Investig Med 2019;67:295-302.